Research programme: hepatitis C virus helicase inhibitors - Vertex Pharmaceuticals

Drug Profile

Research programme: hepatitis C virus helicase inhibitors - Vertex Pharmaceuticals

Latest Information Update: 20 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vertex Pharmaceuticals
  • Class
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; RNA helicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 07 Apr 2004 This programme is still in active development
  • 20 Aug 2001 This programme is still in active development
  • 08 Dec 1998 Preclinical development for Hepatitis C in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top